A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Phase 2 – studying effectiveness and dosage
Conditions:
Complement-Mediated Kidney Disease
Sponsor: Adarx Pharmaceuticals Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time
Incidence and severity of TEAEs
Description
1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 7 participants
БГ